562 related articles for article (PubMed ID: 28363335)
21. Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology.
Zolotovskaia MA; Sorokin MI; Petrov IV; Poddubskaya EV; Moiseev AA; Sekacheva MI; Borisov NM; Tkachev VS; Garazha AV; Kaprin AD; Shegay PV; Giese A; Kim E; Roumiantsev SA; Buzdin AA
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111026
[TBL] [Abstract][Full Text] [Related]
22. An appraisal of drug development timelines in the Era of precision oncology.
Jardim DL; Schwaederle M; Hong DS; Kurzrock R
Oncotarget; 2016 Aug; 7(33):53037-53046. PubMed ID: 27419632
[TBL] [Abstract][Full Text] [Related]
23. Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.
Marquart J; Chen EY; Prasad V
JAMA Oncol; 2018 Aug; 4(8):1093-1098. PubMed ID: 29710180
[TBL] [Abstract][Full Text] [Related]
24. Molecular pathway activation - New type of biomarkers for tumor morphology and personalized selection of target drugs.
Buzdin A; Sorokin M; Garazha A; Sekacheva M; Kim E; Zhukov N; Wang Y; Li X; Kar S; Hartmann C; Samii A; Giese A; Borisov N
Semin Cancer Biol; 2018 Dec; 53():110-124. PubMed ID: 29935311
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine.
Eke I; Makinde AY; Aryankalayil MJ; Ahmed MM; Coleman CN
Cancer Lett; 2016 Nov; 382(1):118-126. PubMed ID: 26828133
[TBL] [Abstract][Full Text] [Related]
26. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
27. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
[TBL] [Abstract][Full Text] [Related]
28. Pediatric oncology enters an era of precision medicine.
Seibel NL; Janeway K; Allen CE; Chi SN; Cho YJ; Glade Bender JL; Kim A; Laetsch TW; Irwin MS; Takebe N; Tricoli JV; Parsons DW
Curr Probl Cancer; 2017; 41(3):194-200. PubMed ID: 28343740
[TBL] [Abstract][Full Text] [Related]
29. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Mateo J; Chakravarty D; Dienstmann R; Jezdic S; Gonzalez-Perez A; Lopez-Bigas N; Ng CKY; Bedard PL; Tortora G; Douillard JY; Van Allen EM; Schultz N; Swanton C; André F; Pusztai L
Ann Oncol; 2018 Sep; 29(9):1895-1902. PubMed ID: 30137196
[TBL] [Abstract][Full Text] [Related]
30. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
[TBL] [Abstract][Full Text] [Related]
31. Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Festino L; Botti G; Lorigan P; Masucci GV; Hipp JD; Horak CE; Melero I; Ascierto PA
Drugs; 2016 Jun; 76(9):925-45. PubMed ID: 27229745
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenomic biomarkers for personalized cancer treatment.
Rodríguez-Antona C; Taron M
J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
[TBL] [Abstract][Full Text] [Related]
33. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
34. Giving Up on Precision Oncology? Not So Fast!
Warner JL
Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
[No Abstract] [Full Text] [Related]
35. Predictive genomic biomarkers.
Kumar R; Amado RG
Curr Top Microbiol Immunol; 2012; 355():173-88. PubMed ID: 21877260
[TBL] [Abstract][Full Text] [Related]
36. The great biomarker chase.
Mortkowitz L
Am J Manag Care; 2012 Feb; 18(1 Spec No.):SP22-3. PubMed ID: 22468869
[No Abstract] [Full Text] [Related]
37. Proteomic profiling predicts drug response to novel targeted anticancer therapeutics.
Lin F; Li Z; Hua Y; Lim YP
Expert Rev Proteomics; 2016; 13(4):411-20. PubMed ID: 26954459
[TBL] [Abstract][Full Text] [Related]
38. A decision support framework for genomically informed investigational cancer therapy.
Meric-Bernstam F; Johnson A; Holla V; Bailey AM; Brusco L; Chen K; Routbort M; Patel KP; Zeng J; Kopetz S; Davies MA; Piha-Paul SA; Hong DS; Eterovic AK; Tsimberidou AM; Broaddus R; Bernstam EV; Shaw KR; Mendelsohn J; Mills GB
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863335
[TBL] [Abstract][Full Text] [Related]
39. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
Villaruz LC; Socinski MA
Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296
[TBL] [Abstract][Full Text] [Related]
40. Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic.
Prudkin L; Nuciforo P
Cell Oncol (Dordr); 2015 Feb; 38(1):39-48. PubMed ID: 25185990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
